Summary & Overview
HCPCS G9223: PJP Prophylaxis for Low CD4 Count
HCPCS Level II code G9223 documents the prescription of Pneumocystis jiroveci pneumonia (PJP) prophylaxis within three months of documenting a CD4+ cell count below 500 cells/mm3 or a CD4 percentage below 15%. This preventive intervention is clinically important because timely prophylaxis reduces the risk of opportunistic PJP infections among patients with significant immunosuppression, affecting outcomes and resource use across outpatient care settings. Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the code’s clinical intent and typical sites of service, plus operational implications for billing and documentation. The publication highlights benchmark considerations, common modifier usage where available, and clinical context around CD4 thresholds that trigger prophylaxis prescribing. It also identifies gaps where specific diagnosis crosswalks, taxonomy mappings, and service-line details are not available in the input. This overview is intended for clinicians, practice managers, and billing professionals seeking clear guidance on when G9223 applies and what elements of documentation and coding warrant attention in national payer environments.
Billing Code Overview
HCPCS Level II code G9223 describes Pneumocystis jiroveci pneumonia (PJP) prophylaxis prescribed within 3 months of a low CD4+ cell count below 500 cells/mm3 or a CD4 percentage below 15%. This code covers the clinical action of prescribing prophylactic therapy aimed at preventing PJP in patients with evidence of significant immunosuppression.
Service type: Outpatient medication prophylaxis management / Preventive infectious disease care
Typical site of service: Outpatient clinic, ambulatory care setting, or other outpatient medical visit where prophylactic therapy is prescribed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult living with HIV who presents to an infectious disease clinic or primary care office after recent laboratory results show a CD4+ T‑lymphocyte count falling below 500 cells/mm³ or a CD4 percentage under 15%. The clinician documents eligibility for Pneumocystis jiroveci pneumonia (PJP) prophylaxis and prescribes a prophylactic antimicrobial (commonly trimethoprim‑sulfamethoxazole). The workflow includes medication counseling, assessment of sulfa allergy and renal function, verification of adherence barriers, immunization review, and entry of the prescription and clinical rationale into the electronic health record. Typical sites of service are outpatient clinics (infectious disease, HIV specialty, or primary care), community health centers, and telehealth visits where a prescription is issued and documented within three months of the qualifying CD4 result. Billing under G9223 documents that PJP prophylaxis was prescribed within three months of a CD4 count below 500 cells/mm3 or a CD4 percentage below 15%.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work or complexity beyond usual is documented for the visit where prophylaxis was initiated (e.g., extensive counseling, multi‑system review). |